Literature DB >> 29974955

BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.

Andrea Visentin1,2, Silvia Imbergamo1, Edoardo Scomazzon1, Stefano Pravato1, Federica Frezzato1,2, Laura Bonaldi3, Marco Pizzi4, Stefania Vio5, Michele Gregianin6, Marta Burei7, Monica Facco1,2, Gianpietro Semenzato1,2, Francesco Piazza1,2, Livio Trentin1,2.   

Abstract

Entities:  

Keywords:  chronic lymphocytic leukaemia; ibrutinib; idelalisib; lenalidomide; richter syndrome

Mesh：

Substances：

Year:  2018        PMID： 29974955     DOI： 10.1111/bjh.15440

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

1.  Rapid and complete response to idelalisib in a case of Richter syndrome.

Authors:  Cristina Bagacean; Mihnea Zdrenghea; Hussam Saad; Christian Berthou; Yves Renaudineau; Adrian Tempescul
Journal:  Onco Targets Ther       Date:  2019-02-13       Impact factor: 4.147

2.  Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.

Authors:  Isha Kapoor; Yue Li; Arishya Sharma; Huayuan Zhu; Juraj Bodo; Wei Xu; Eric D Hsi; Brian T Hill; Alexandru Almasan
Journal:  Cell Death Dis       Date:  2019-12-04       Impact factor: 8.469

Review 3.  Richter Syndrome.

Authors:  Adalgisa Condoluci; Davide Rossi
Journal:  Curr Oncol Rep       Date:  2021-02-12       Impact factor: 5.075

Review 4.  Novel Approaches for the Treatment of Patients with Richter's Syndrome.

Authors:  Andrea Iannello; Silvia Deaglio; Tiziana Vaisitti
Journal:  Curr Treat Options Oncol       Date:  2022-03-16

Review 5.  Biology and Treatment of Richter Transformation.

Authors:  Adalgisa Condoluci; Davide Rossi
Journal:  Front Oncol       Date:  2022-03-22       Impact factor: 6.244

Review 6.  Richter Syndrome: From Molecular Pathogenesis to Druggable Targets.

Authors:  Samir Mouhssine; Gianluca Gaidano
Journal:  Cancers (Basel)       Date:  2022-09-24       Impact factor: 6.575

7.  The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation.

Authors:  Andrea Visentin; Laura Bonaldi; Gian Matteo Rigolin; Francesca Romana Mauro; Annalisa Martines; Federica Frezzato; Stefano Pravato; Leila Romano Gargarella; Maria Antonella Bardi; Maurizio Cavallari; Eleonora Volta; Francesco Cavazzini; Mauro Nanni; Monica Facco; Francesco Piazza; Anna Guarini; Robin Foà; Gianpietro Semenzato; Antonio Cuneo; Livio Trentin
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

8.  Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells.

Authors:  Anna Dalla Pietà; Elisa Cappuzzello; Roberta Sommaggio; Antonio Rosato; Pierangela Palmerini; Annavera Ventura; Andrea Visentin; Giuseppe Astori; Katia Chieregato; Valentina Mozzo; Omar Perbellini; Maria Chiara Tisi; Livio Trentin; Carlo Visco; Marco Ruggeri
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.